IceCure Medical (ICCM) EBITDA (2020 - 2026)

IceCure Medical (ICCM) has 7 years of EBITDA data on file, last reported at $4.2 million in Q1 2026.

• On a quarterly basis, EBITDA rose 16.13% year-over-year to $4.2 million in Q1 2026; TTM through Mar 2026 was $15.7 million, a 0.12% change from a year earlier, with the FY2025 full-year figure at $15.1 million, down 3.84% from the prior year.
• EBITDA for Q1 2026 stood at $4.2 million, up from $4.2 million in the prior quarter.
• Over the last five years, EBITDA for ICCM reached as high as $4.5 million in Q4 2024 and fell as low as -$29.5 million in Q4 2022.
• Historically, EBITDA has averaged $160117.6 across 5 years, with a median of $4.1 million in 2023.
• On a YoY basis, EBITDA climbed as much as 270.91% in 2022 and fell as far as 81.04% in 2022.
• Year by year, EBITDA stood at -$29.5 million in 2022, then rose by 6.12% to -$27.7 million in 2023, then surged by 116.31% to $4.5 million in 2024, then fell by 6.83% to $4.2 million in 2025, then gained by 0.74% to $4.2 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were $4.2 million in Q1 2026, $4.2 million in Q4 2025, and $3.8 million in Q3 2025.